Skip to main content
SpringerLink
Log in

Objectives and achievements of medicines regulation in the UK

  • Chapter
International Medicines Regulations

Part of the book series: CMR Workshop Series ((CMRWS))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jayasuriya D C (1985). Regulation of Pharmaceuticals in Developing Countries. (Geneva: World Health Organization),

    Google Scholar 

  2. Dunlop D (1967). The Assessment of the Safety of Drugs and the role of Government in their Control. J. Clin. Pharmacol. 1, 184–92

    Google Scholar 

  3. Medicines Act (1968). (London: Her Majesty’s Stationery Office)

    Google Scholar 

  4. Commission of the European Communities (1984). The Rufes Governing Medicaments in the European Community. (Luxembourg: Office for Official Publications of the European Communities)

    Google Scholar 

  5. Zbinden G (1981). Scope and Limitation of Animal Models for the Prediction of Human Toxicity. In Brown SS and Davies DS (eds). Organ-Directed Toxicity, pp. 3–7. (Oxford: Pergamon Press)

    Google Scholar 

  6. Fletcher A P (1978). Drug Safety Testing and Subsequent Clinical Experience. J. R. Soc. Med. 71, 693–6

    PubMed  CAS  Google Scholar 

  7. Griffin J P (1983). Repeat-dose long-term toxicity studies. In Balls M, Riddell R J and Worden A N (eds). Animals and Alternatives in Toxicity Testing, pp. 98–103. (London: Academic Press)

    Google Scholar 

  8. Laurence D R, Maclean A and Weatherall M (1984). Safety Testing of New Drugs. (London: Academic Press)

    Google Scholar 

  9. Rawlins M D and Thompson J W (1985). Mechanisms of adverse drug reactions. In Davies D M (ed). Textbook of Adverse Drug Reactions pp. 12–38, (Oxford: Oxford University Press)

    Google Scholar 

  10. Royal Society Study Group (1983). Risk Assessment. (London: The Royal Society)

    Google Scholar 

  11. Rawlins M D (1987). Advantages and disadvantages of different techniques of post-marketing surveillance. In Mann R D (ed). Adverse Drug Reactions pp. 67–74. (Carnforth: Parthenon Publishing)

    Google Scholar 

  12. Rawlins M D (1988). Spontaneous reporting of adverse drug reactions I: the data. Br. J. Clin. Pharmacol. 26, 1–6

    PubMed  CAS  Google Scholar 

  13. Rawlins M D (1988). Spontaneous reporting of adverse drug reactions II: uses. Br. J. Clin. Pharmacol. 26, 7–12

    PubMed  CAS  Google Scholar 

  14. Grahame-Smith D G (1987). Adverse drug reaction monitoring: the way forward. In Mann R D (ed). Adverse Drug Reactions pp. 201–14. (Carnforth: Parthenon Publishing)

    Google Scholar 

  15. Dukes G (1985). The Effect of Drug Regulation. (Lancaster: MTP Press)

    Google Scholar 

  16. Medewar C (1987). Observations on the UK Government’s 1987 Study of Control of Medicines. (London: Social Audit)

    Google Scholar 

  17. Green D G (1987). Medicines in the Marketplace. (London: IEA Health Unit)

    Google Scholar 

  18. Rawlins M D (1988). Drug regulation: evolution or revolution? Br. Med. J., 296, 379–80

    Article  CAS  Google Scholar 

  19. Rawlins M D (1984). Doctors and the drug makers, Lancet, 2, 276–8

    Article  PubMed  CAS  Google Scholar 

  20. Office of Health Economics (1986). Crisis in Research. (London: Office of Health Economics)

    Google Scholar 

Download references

Authors
  1. M. D. Rawlins
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Welsh School of Pharmacy, Cardiff, UK

    Stuart R. Walker (Director of the Centre for Medicines Research Carshalton, and Honorary Professor) (Director of the Centre for Medicines Research Carshalton, and Honorary Professor)

  2. The Association of the British Pharmaceutical Industry, London, UK

    John P. Griffin (Director, Professional Head of the Medicines Division) (Director, Professional Head of the Medicines Division)

  3. DHSS, London, UK

    John P. Griffin (Director, Professional Head of the Medicines Division) (Director, Professional Head of the Medicines Division)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Rawlins, M.D. (1989). Objectives and achievements of medicines regulation in the UK. In: Walker, S.R., Griffin, J.P. (eds) International Medicines Regulations. CMR Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0857-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0857-4_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6873-4

  • Online ISBN: 978-94-009-0857-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation